ArticleJournal of family medicine and primary care2025
Cutaneous and systemic manifestations of EGFR inhibitor therapy: A case of PRIDE syndrome.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EGFR inhibitors have revolutionized the treatment of advanced malignancies by targeting cancer cells specifically. The "PRIDE" complex encompasses a range of cutaneous adverse effects linked to EGFR inhibition therapy, including acneiform eruptions, xerosis, eczema, paronychia, and hair and nail changes. Cutaneous toxicities are among the most reported adverse events in this context. This report presents a case illustrating the dermatological side effects of EGFR inhibition therapy. The case involves a 73-year-old man with colon cancer undergoing (folinic acid, fluorouracil, irinotecan) + cetuximab treatment, presenting with diffuse rash, severe xerosis, bilateral scleral congestion, hyperpigmentation, nail changes, abdomen and toe ulcers, and skin infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.